(Q83255457)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21252928%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

editorial

0 references

title

Comparative effectiveness: the fourth hurdle in drug development and a role for clinical pharmacology (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21252928%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

P K Honig

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21252928%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

1 February 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21252928%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

20 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21252928%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

volume

89

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21252928%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21252928%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

151-156

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21252928%20AND%20SRC:MED&resulttype=core&format=json

The economics of drug development: a grim reality and a role for clinical pharmacology

20 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.302

7 January 2021

Location of pharmaceutical innovation: 2000-2009

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.302

7 January 2021

Systematic reviews and meta-analyses in the new age of transparency

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.302

7 January 2021

Comparative effectiveness research: critically intertwined with health care reform and the future of biomedical innovation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.302

7 January 2021

The (possible) impact of comparative effectiveness research on pharmaceutical industry decision making

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.302

7 January 2021

Developments in post-marketing comparative effectiveness research

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.302

7 January 2021

Meta-analysis and epidemiologic studies in drug development and postmarketing surveillance

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.302

7 January 2021

Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.302

7 January 2021

Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.302

7 January 2021

Pharmacoeconomics in the era of individualized medicine

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.302

7 January 2021

Risk management of marketed drugs: FDA and the interface with the practice of medicine

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.302

7 January 2021

Identifiers

DOI

10.1038/CLPT.2010.302

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21252928%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference